Українська Русский English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2013; 59(3): 126-134


Mesenchymal stem cells and their immunological properties

Lisianyĭ MI

    Institute of Neurosurgery named after acad.A.P.Romodanov of National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz59.03.126

Abstract

Mesenchymal stem cells (MSC) are found in a variety of tissues, including bone marrow, skin and adipose tissue and can be expanded easily in vitro. MSC are thought to have tissue regenerative properties, in the first place via their multilineage differentiation capacity. In addition, MSC have potent immunomodulatory capacity. They inhibit the proliferation of T cells and inhibit dendritic cell maturation. These properties make MSC promising for a diversity of clinical applications; for example, for the prevention and treatment of autoimmune diseases and bone marrow rejection. Different studies have attributed the immunosuppressive effect of MSC to different immunosuppressive factors. These include indoleamine 2,3-dioxygenase (IDO), HLA-G, nitric oxide, interleukines. The long-term ability of allogeneic MSCs to preserve function in the infarcted heart is limited by a biphasic immune response whereby they transition from an immunoprivileged to an immunogenic state after differentiation, which is associated with an alteration in major histocompatibility complex--immune antigen profile. These findings provide critical information about the immunosuppression of MSCs and for better application of MSCs in treating immune disorders.

Keywords: Mesenchymal stem cells;Immunosuppression;Cytokine; HLA-antigens

References

  1. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses . Blood.200. 105. P.1815-1822.
  2.  
  3. Al-Refu K., Goodfield M. Hair follicle stem cells inthe pathogenesis of the scarring process in cutaneouslupus erythematosus . Autoimmun. Rev. 2009. 8.P.474-477. CrossRef PubMed
  4.  
  5. Ankrum J., Karp J.M. Mesenchymal stem cell therapy: twosteps forward, one step back . Trends Mol Med. 2010.-16. P.203-209.
  6.  
  7. Atoui R., Shum-Tim D., Chiu R.C. Myocardial regenerativetherapy: immunologic basis for the potential"universal donor cells". Ann Thorac. Surg. 2008. 86. P.327-334. CrossRef PubMed
  8.  
  9. Augello A., Tasso R., Negrini S.M., Cancedda R., PennesiG. Cell therapy using allogeneic bone marrowmesenchymal stem cells prevents tissue damage incollagen-induced arthritis. Arthritis Rheum. 2007. 56. P.1175-1186. CrossRef PubMed
  10.  
  11. Cai L., Johnstone B.H., Cook T.G., Tan J., Fishbein M.C.,Chen P.S., March K.L. IFATS collection: Human adiposetissue-derived stem cells induce angiogenesis and nervesprouting following myocardial infarction, in conjunctionwith potent preservation of cardiac function . Stem Cells.-2009. 27. P.230-237. CrossRef PubMed PubMedCentral
  12.  
  13. Carosella E.D., Moreau P., Le Maoult J. HLA-G molecules:Frommaternal-fetal tolerance to tissue acceptance. Adv. Immunol. 2003. 81. P.199-252. CrossRef  
  14. Choi E.W., Shin I.S., Lee H.W., Park S.Y., Park J.H., NamM.H., Kim J.S., Woo S.K., Yoon E.J., Kang S.K., RaJ.C., Youn H.Y., Hong S.H. Transplantation of CTLA4Iggene-transduced adipose tissue-derived mesenchymalstem cells reduces inflammatory immune response andimproves Th1/Th2 balance in experimental autoimmunethyroiditis . J. Gene Med. 2011 13. P.3-16. CrossRef PubMed
  15.  
  16. Choi Y.H., Kurtz A., Stamm C. Mesenchymal stem cellsfor cardiac cell therapy . Hum Gene Ther. 2011. 22.P.3-17. CrossRef PubMed
  17.  
  18. Colonna M., Navarro F., Bellon T. A common inhibitoryreceptor for major histocompatibility complex class Imolecules on human lymphoidand myelomonocyticcells. J. Exp. Med. 1997. 6. P.1809-1818. CrossRef  
  19. Corcione A., Benvenuto F., Ferretti E., Giunti D., CappielloV., Cazzanti F., Risso M., Gualandi F., MancardiG.L., Pistoia V., Uccelli A. Human mesenchymal stemcells modulate B-cell functions . Blood. 2006. 107.P.367-372. CrossRef PubMed
  20.  
  21. Di Nicola M., Carlo-Stella C., Magni M. Human bonemarrow stromal cells suppress T-lymphocyte proliferationinduced by cellular or nonspecific mitogenic stimuli. Ibid. 2002. 99. P. 3838-3843.
  22.  
  23. Djouad F., Bouffi C., Ghannam S., Noil D., Jorgensen C.Mesenchymal stem cells: innovative therapeutic toolsfor rheumatic diseases . Nat. Rev. Rheumatol. 2009.5. P.392-399.
  24.  
  25. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P,Bony C, Apparailly F, Cantos C, Jorgensen C, NoelD. Mesenchymal stem cells inhibit the differentiationof dendritic cells through an interleukin-6-dependentmechanism . Stem Cells. 2007. 25. P.2025-2032. CrossRef PubMed
  26.  
  27. Djouad F., Plence P., Bony C. Immunosuppressive effectof mesenchymal stem cells favors tumor growth in allogeneicanimals . Blood. 2003. 102. P.3837-3844. CrossRef PubMed
  28.  
  29. Dominici M., Le Blanc K., Mueller I., Slaper-CortenbachI., Marini F., Krause D., Deans R., Keating A., ProckopD., Horwitz E. Minimal criteria for defining multipotentmesenchymal stromal cells. The International Societyfor Cellular Therapy position statement . Cytotherapy.2006. 8. P.315-317. CrossRef PubMed
  30.  
  31. Edwards T.M., Rickard N.S. New perspectives on themechanisms through which nitric oxide may affectlearning and memory processes . Neurosci. Biobehav.Rev. 2007. 31. P. 413-425. CrossRef PubMed
  32.  
  33. Garcia-Gomez I., Elvira G., Zapata A.G., Lamana M.L.,Ramorez M., Castro J.G., Arranz M.G., Vicente A.,Bueren J., Garcia-Olmo D. Mesenchymal stem cells:biological properties and clinical applications . Exp.Opin. Biol. Ther. 2010. 10. P.1453-1468. CrossRef PubMed
  34.  
  35. Grohmann U., Orabona C., Fallarino F. CTLA-4-Igregulates tryptophan catabolism in vivo. Nat. Immunol.-2002. 3. P. 1097-1101. CrossRef PubMed
  36.  
  37. Hare J.M., Traverse J.H., Henry T.D., Dib N., StrumpfR.K., Schulman S.P. A randomized, double-blind,placebo-controlled, dose-escalation study of intravenousadult human mesenchymal stem cells (prochymal) afteracute myocardial infarction . J. Amer. Coll Cardiol. 2009. 54. P.2277-2286. CrossRef PubMed PubMedCentral
  38.  
  39. Heiss C., Keymel S., Niesler U. Ziemann J., Kelm M., KalkaC. Impaired progenitor cell activity in age-related endothelialdysfunction . Ibid. 2005. 45. P.1441-1448.
  40.  
  41. Hulkower K., Brosnan C.F., Aquino D.A. Expression ofCSF-1, c-fms, and MCP-1 in the central nervous systemof rats with experimental allergic encephalomyelitis . J.Immunol. 1993. 150. P. 2525-2533. PubMed
  42.  
  43. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D.,Mao N. Human mesenchymal stem cells inhibit differentiationand function of monocyte-derived dendritic cells. Blood. 2005. 105. P.4120-4126. CrossRef PubMed
  44.  
  45. Jiang Y., Jahagirdar B.N., Reinhardt R.L., Schwartz R.E.,Keene C.D., Ortiz-Gonzalez X.R., Reyes M., Lenvik T.,Lund T., Blackstad M., Du J., Aldrich S., Lisberg A., LowW.C., Largaespada D.A., Verfaillie C.M. Pluripotency ofmesenchymal stem cells derived from adult marrow. Nature. 2002. 418. P.41-49. CrossRef PubMed
  46.  
  47. Krampera M., Glennie S., Dyson J., Scott D., Laylor R.,Simpson E., Dazzi F. Bone marrow mesenchymal stemcells inhibit the response of naive and memory antigenspecificT cells to their cognate peptide . Blood. 2003.101. P.3722-3729.
  48.  
  49. Le Blanc K., Ringden O. Immunomodulation by mesenchymalstem cells and clinical experience . J. Intern.Med. 2007. 262. P.509-525 CrossRef PubMed
  50.  
  51. Lee O.K., Kuo T.K., Chen W.M., Lee K.D., Hsieh S.L.,Chen T.H. Isolation of multipotent mesenchymal stemcells from umbilical cord blood . Blood. 2004. 103.P.1669-1675. CrossRef PubMed
  52.  
  53. Lila N., Rouas-Freiss N., Dausset J. Soluble HLA-Gprotein secretedby allo-specific CD4_ T cells suppressesthe allo-proliferative response:A CD4_ T cell regulatorymechanism . Proc. Natl. Acad. Sci. USA. 2001. 98.P.12150-12155. CrossRef PubMed PubMedCentral
  54.  
  55. Liu H., Liu L., Fletcher B.S. Sleeping Beauty-based genetherapy with indoleamine 2,3-dioxygenase inhibits lungallograft fibrosis . FASEB J. 2006. 20. P.2384-2386. CrossRef PubMed
  56.  
  57. Majumdar M.K., Keane-Moore M., Buyaner D. Characterizationfunctionality of cell surface molecules onhuman mesenchymal stemcells . J. Biomed. Sci. 2003. 10. P.228-241. CrossRef
  58.  
  59. McMaster M.T., Librach C.L., Zhou Y. Human placentalHLA-Gexpression is restricted to differentiated cytotrophoblasts. J. Immunol. 1995. 154. P.3771-3778. PubMed
  60.  
  61. Meirelles Lda S., Fontes A.M., Covas D.T., Caplan A.I.Mechanisms involved in the therapeutic properties ofmesenchymal stem cells . Cytokine Growth Factor Rev.2009. 20. P.419-427. CrossRef PubMed
  62.  
  63. Meisel R., Zibert A., Laryea M. Human bone marrow stromalcells inhibit allogeneic T-cell responses by indoleamine2,3-dioxygenase-mediated tryptophan degradation. Blood. 2004. 103. P. 4619-4621. CrossRef PubMed
  64.  
  65. Mellor A.L., Munn D.H. IDO expression by dendriticcells: Tolerance and tryptophan catabolism . Nat. Rev.Immunol. 2004. 4. P. 762-774. CrossRef PubMed
  66.  
  67. Muller A.J., Prendergast G.C. Indoleamine 2,3-dioxygenasein immune suppression and cancer. Curr CancerDrug Targets. 2007. 7. P. 31-40. CrossRef PubMed
  68.  
  69. Munn D.H., Mellor A.L. IDO and tolerance to tumors. Trends Mol. Med. 2004. 10. P. 15-18. CrossRef PubMed
  70.  
  71. Nasef A., Chapel A., Mazurier C. Identification of IL-10and TGF-beta transcripts involved in the inhibition ofT-lymphocyte proliferation during cell contact with humanmesenchymal stem cells . Gene Exp. 2007. 13.P.217-226. CrossRef PubMed
  72.  
  73. Nauta A.J., Fibbe W.E. Immunomodulatory propertiesof mesenchymal stromal cells . Blood. 2007. 110.P.3499-3506. CrossRef PubMed
  74.  
  75. Oh J.Y., Kim M.K., Shin M.S., Lee H.J., Ko J.H., WeeW.R., Lee J.H. The anti-inflammatory and antiangiogenicrole of mesenchymal stem cells in corneal wound healingfollowing chemical injury . Stem Cells. 2008. 26.P.1047-1055 CrossRef PubMed
  76.  
  77. Papadaki H.A., Kritikos H.D., Gemetzi C., Koutala H.,Marsh J.C., Boumpas D.T., Eliopoulos G.D. Bone marrowcell reserve and function and stromal cellfunction are defective in rheumatoid arthritis: evidencefor a tumor necrosis factor alphamediated effect. Blood.2002. 99. P.1610-1619. CrossRef PubMed
  78.  
  79. Papadaki H.A., Tsagournisakis M., Mastorodemos V., PontikoglouC., Damianaki A., Pyrovolaki K., StamatopoulosK., Fassas A., Plaitakis A., Eliopoulos G.D. Normal bonehematopoietic stem cell reserves and normalstromal cell function support the use of autologous stemcell transplantation in patients with multiple sclerosis. Bone Marrow Transplant. 2005. 36. P.1053-1063. CrossRef PubMed
  80.  
  81. Parekkadan B., Milwid J.M. Mesenchymal stem cells as therapeutics . Annu Rev Biomed. Eng. 2010. 12. P.87-117. CrossRef PubMed PubMedCentral
  82.  
  83. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells . Science. 1999. 284. P.143-147. CrossRef PubMed
  84.  
  85. Pittenger M.F., Martin B.J. Mesenchymal stem cells and their potential as cardiac therapeutics . Circulat. Res. 2004. 36. P.95-99. CrossRef  
  86. Ra J., Kang S., Shin S. Stem cell treatment for patients with autoimmune disease by systemic infusion of cultureexpanded autologous adipose tissue derived mesenchymal stem cells . J. Transl. Med. 2011. 9. P.181-198. PubMed PubMedCentral
  87.  
  88. Ra J.C., Shin I.S., Kim S.H., Kang S.K., Kang B.C., Lee H.Y., Kim Y.J., Jo J.Y., Yoon E.J., Choi H.J., Kwon E. Safety of intravenous infusion of human adipose tissuederived mesenchymal stem cells in animals and humans . Stem Cells Dev. 2011. 20. P.1295-1296. CrossRef PubMed
  89.  
  90. Rasmusson I., Ringd N.O., Sundberg B., Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms . Exp. Cell Res. 2005. 305. P.33-41. CrossRef PubMed
  91.  
  92. Ren G., Zhang L., Zhao X. Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide . Cell Stem. Cell. 2008. 2. P. 141-150. CrossRef PubMed
  93.  
  94. Ren G., Zhang L., Zhao X., Xu G., Zhang Y., Roberts A.I., Zhao R.C., Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide . Stem Cells. 2008. 2. P.141-150.
  95.  
  96. Ren G., Su F., Zhang L. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression . Stem Cells. 2009. 27. P.1954-1962. CrossRef PubMed
  97.  
  98. Ristich V., Liang S., Zhang W. Tolerization of dendritic cells byHLA-G . Eur. J. Immunol. 2005. 35. P.1133-1142. CrossRef PubMed
  99.  
  100. Rouas-Freiss N., Marchal R.E., Kirszenbaum M. The alpha1 domainof HLA-G1 and HLA-G2 inhibits cytotoxi city induced by natural killercells: Is HLA-G the public ligand for natural killer cell inhibitoryreceptors? . Proc. Natl. Acad. Sci. USA. 1997. 94. P.5249-5254. CrossRef PubMed
  101.  
  102. Sato K., Ozaki K., Oh I. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells . Blood. 2007. 109. P.228-234. CrossRef PubMed
  103.  
  104. Selmani Z., Naji A., Zidi I., Favier B., Gaiffe E., Obert L., Borg C., Saas P., Tiberghien P., Rouas-Freiss N., Carosella E.D., Deschaseaux F. Epub 2007 Oct 11. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells . Stem. Cells. 2008. 26. P.212-222. CrossRef PubMed
  105.  
  106. Si Y.L., Zhao Y.L., Hao H.J., Fu X.B., Han W.D. MSC: Biological characteristics, clinical ap. plications and their outstanding concerns . Ageing Res Rev. 2011. 10. P.93-103. CrossRef PubMed
  107.  
  108. Spaggiari G.M., Capobianco A., Abdelrazik H., Becchetti F., Mingari M.C., Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2, 3-dioxygenase and prostaglandin E2 . Blood. 2008. 111. P.1327-1333. CrossRef PubMed
  109.  
  110. Stamler J.S., Singel D.J., Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms . Science. 1992. 258. P 1898-1902. CrossRef PubMed
  111.  
  112. Togel F., Weiss K., Yang Y., Hu Z., Zhang P., Westenfelder C. Vasculotropic, paracrine a ctions of infused mesenchymal stem cells are important to the recovery from acute kidney injury . Amer. J. Physiol. Renal. Physiol. 2007. 292. P.1626-1635. CrossRef PubMed
  113.  
  114. Uyttenhove C., Pilotte L., Theate I. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase . Nat. Med. 2003. 9. P. 1269-1274. CrossRef PubMed
  115.  
  116. Xi-Ping Huang, Ph.D. Zhuo Sun M.D., Yasuo Miyagi M.D., Heather McDonald Kinkaid, MSc Li Zhang M.D., PhD Differentiation of Allogeneic Mesenchymal Stem Cells Induces Immunogenicity and Limits Their LongTerm Benefits for Myocardial Repair . Circulation. 2010. 122. P.2419-2429. CrossRef PubMed
  117.  
  118. Yasez R., Lamana M.L., Garcta-Castro J., Colmenero I., Ramtrez M., Bueren J.A. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versushost disease . Stem Cells. 2006. 24. P.2582-2591. CrossRef PubMed
  119.  
  120. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G., Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy . Blood. 2005. 106. P.1755-1761. CrossRef PubMed
  121.  
  122. Zhang M., Mal N., Kiedrowski M., Chacko M., Askari A.T., Popovic Z.B., Koc O.N., Penn MS. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction . FASEB J. 2007. 21. P.3197-3207. CrossRef PubMed
  123.  

© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2019.